In a new interview with Redeye’s Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2).
Watch the full interview here: Redeye Interview: Neola Medical Q2 2025 with CEO Hanna Sjöström
Access the research update and additional insights from Redeye here: https://www.redeye.se/company/neola-medical